{"id":"haplo-hct","safety":{"commonSideEffects":[{"rate":null,"effect":"Graft-versus-host disease (GVHD)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Relapse of underlying malignancy"},{"rate":null,"effect":"Organ toxicity"},{"rate":null,"effect":"Graft failure or delayed engraftment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Haplo-HCT leverages haploidentical (half-matched) donors, which are more readily available than fully matched donors, by employing post-transplant cyclophosphamide (PTCy) to selectively eliminate alloreactive T cells while preserving beneficial graft-versus-leukemia effects. This approach expands access to hematopoietic stem cell transplantation for patients with hematologic malignancies or bone marrow disorders who lack matched sibling or unrelated donors.","oneSentence":"Haplo-HCT is a haploidentical hematopoietic cell transplantation approach that enables transplantation from half-matched donors by using post-transplant cyclophosphamide and other immunosuppressive strategies to prevent graft-versus-host disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:59.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (acute leukemia, chronic leukemia, lymphoma, myeloma) in patients lacking matched donors"},{"name":"Severe aplastic anemia and other bone marrow failure syndromes"}]},"trialDetails":[{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT02171104","phase":"PHASE2","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-07-10","conditions":"Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome","enrollment":149},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT04191187","phase":"PHASE2","title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-12-06","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia","enrollment":34},{"nctId":"NCT07252050","phase":"PHASE1, PHASE2","title":"Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-01-01","conditions":"Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant","enrollment":24},{"nctId":"NCT06195891","phase":"PHASE1","title":"Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-05-24","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma","enrollment":63},{"nctId":"NCT06984536","phase":"PHASE2","title":"Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-21","conditions":"Myelodysplastic Syndrome, Acute Leukemia","enrollment":40},{"nctId":"NCT02988466","phase":"PHASE2","title":"Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-01-24","conditions":"Hematologic Malignancies","enrollment":78},{"nctId":"NCT02646839","phase":"PHASE2","title":"KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children","status":"ENROLLING_BY_INVITATION","sponsor":"Michael Pulsipher","startDate":"2015-10","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT02100891","phase":"PHASE2","title":"Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors","status":"TERMINATED","sponsor":"Monica Thakar","startDate":"2013-03-20","conditions":"Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma","enrollment":15},{"nctId":"NCT05789615","phase":"","title":"Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-04-01","conditions":"CMV Infection, Hematopoietic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT06423131","phase":"NA","title":"Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT","status":"RECRUITING","sponsor":"Sijia Gu","startDate":"2024-05-26","conditions":"Graft-Versus-Host Disease, Hematopoietic Stem Cell Transplantation, Child, Only","enrollment":110},{"nctId":"NCT06381817","phase":"PHASE3","title":"Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-04-01","conditions":"Acute T Cell Lymphoblastic Leukemia, Haploidentical Hematopoietic Stem Cell Transplantation, Cord Blood","enrollment":146},{"nctId":"NCT04666025","phase":"","title":"SARS-CoV-2 Donor-Recipient Immunity Transfer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-09-23","conditions":"Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT03719534","phase":"PHASE3","title":"Haplo HCT vs Haplo-cord HCT for Patients With AML","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2017-06-01","conditions":"Hematopoietic Stem Cell Transplantation, Haplo-identical Donor, Cord Blood Unit","enrollment":134},{"nctId":"NCT00002663","phase":"PHASE1, PHASE2","title":"Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies","status":"COMPLETED","sponsor":"Atara Biotherapeutics","startDate":"1995-03","conditions":"EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma","enrollment":58},{"nctId":"NCT04686929","phase":"PHASE1, PHASE2","title":"Abatacept s.c. for aGVHD Prevention in Haplo-HCT","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-06-01","conditions":"Abatacept, Acute-graft-versus-host Disease, Haplo-identical HCT","enrollment":29},{"nctId":"NCT03018223","phase":"PHASE1","title":"Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-01-31","conditions":"Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia","enrollment":32},{"nctId":"NCT03988582","phase":"PHASE2","title":"Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-06-11","conditions":"EBV Lymphomas, EBV-associated Malignancies","enrollment":""},{"nctId":"NCT03365661","phase":"PHASE2","title":"QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML","status":"WITHDRAWN","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-10-30","conditions":"High-Risk Acute Myeloid Leukemia, Treatment-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT03298399","phase":"PHASE1","title":"Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2017-12-21","conditions":"Sickle Cell Disease","enrollment":""},{"nctId":"NCT00957931","phase":"PHASE2","title":"Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-03","conditions":"Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":141,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Haplo-HCT","genericName":"Haplo-HCT","companyName":"The First Affiliated Hospital of Soochow University","companyId":"the-first-affiliated-hospital-of-soochow-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"Haplo-HCT is a haploidentical hematopoietic cell transplantation approach that enables transplantation from half-matched donors by using post-transplant cyclophosphamide and other immunosuppressive strategies to prevent graft-versus-host disease. Used for Hematologic malignancies (acute leukemia, chronic leukemia, lymphoma, myeloma) in patients lacking matched donors, Severe aplastic anemia and other bone marrow failure syndromes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}